Next Article in Journal
Interleukin 12 a Key Immunoregulatory Cytokine in Infection Applications
Previous Article in Journal
Covalent Anchoring of Chloroperoxidase and Glucose Oxidase on the Mesoporous Molecular Sieve SBA-15
Int. J. Mol. Sci. 2010, 11(2), 779-788; doi:10.3390/ijms11020779
Communication

Mutagenicity of New Lead Compounds to Treat Sickle Cell Disease Symptoms in a Salmonella/Microsome Assay

1,* , 2, 3 and 1
1 Lapdesf–Laboratório de Pesquisa e Desenvolvimento de Fármacos, Departamento de Fármacos e Medicamentos, Faculdade de Ciências Farmacêuticas, Univ Estadual Paulista–UNESP, Rodovia Araraquara Jaú Km. 01, 14801-902, Araraquara, SP, Brazil 2 Departamento de Ciências Biológicas, Faculdade de Ciências Farmacêuticas, Univ Estadual Paulista–UNESP, Rodovia Araraquara Jaú Km. 01, 14801-902, Araraquara, SP, Brazil 3 LASSBio–Laboratório de Avaliação e Síntese de Substâncias Bioativas, Faculdade de Farmácia, Univ Federal do Rio de Janeiro–UFRJ, Centro de Ciências da Saúde, Cidade Universitária, Ilha do Fundão, 21.944-190–Rio de Janeiro, RJ, Brazil
* Author to whom correspondence should be addressed.
Received: 15 January 2010 / Accepted: 10 February 2010 / Published: 25 February 2010
(This article belongs to the Section Biochemistry, Molecular Biology and Biophysics)
View Full-Text   |   Download PDF [191 KB, uploaded 19 June 2014]   |  

Abstract

A series of phthalimide derivatives planned as drugs candidates to treat the symptoms of sickle cell anemia were evaluated in a mutagenicity test using strains of Salmonella typhimurium TA100 and TA102, without and with addition of S9 mixture, with the aim to identify the best structural requirements for a drug candidate without genotoxic activity. The compounds (1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl nitrate (1); (1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl nitrate (2); 3-(1,3-dioxo-1,3-dihydro-2H-iso-indol-2-yl)benzyl nitrate (3); 4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-N-hydroxy-benzenesulfonamide (4); 4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)benzyl nitrate (5) and 2-[4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)phenyl]ethyl nitrate (6) presented mutagenic potency ranging between 0-4,803 revertants/μmol. These results allowed us to propose that a methyl spacer linked to a nitrate ester subunit associated to meta aromatic substitution decreases mutagenicity.
Keywords: AMES test; mutagenicity; sickle cell; phthalimide derivatives AMES test; mutagenicity; sickle cell; phthalimide derivatives
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).
SciFeed

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote |
RIS
MDPI and ACS Style

Dos Santos, J.L.; Varanda, E.A.; Lima, L.M.; Chin, C.M. Mutagenicity of New Lead Compounds to Treat Sickle Cell Disease Symptoms in a Salmonella/Microsome Assay. Int. J. Mol. Sci. 2010, 11, 779-788.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert